Skip to main content
. Author manuscript; available in PMC: 2020 Apr 1.
Published in final edited form as: Neuropharmacology. 2019 Jan 3;148:139–150. doi: 10.1016/j.neuropharm.2018.12.031

Figure 5.

Figure 5.

Grouped and individual active nosepoke entries during reinstatement rounds 1–3 (N=20). *Indicates significant difference from average responding during two extinction sessions immediately preceding a round of reinstatement tests (see “Ext” on the x axis of panels A, C, and E). EV- Essential Value. Chamber locomotion on panels A, C, and E is visualized using a point size with all point sizes normalized across these panels for accuracy and ease of visual data assessment between these panels.